Literature DB >> 8630897

Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy.

D L Page1, W D Dupont, L W Rogers, R A Jensen, P A Schuyler.   

Abstract

BACKGROUND: The stratification of ductal carcinoma in situ (DCIS) of the human breast into prognostically relevant categories by size and histologic pattern is a current concern. Few studies have been able to follow women after the identification of any type of DCIS when they have had biopsy only.
METHODS: This is an extension of a follow-up study of a group of 28 women with small, noncomedo ductal carcinomas in situ that were excised by biopsy only, published in 1982. All these women have now been successfully followed for an average of almost 30 years.
RESULTS: The overall risk of development of invasive carcinoma for these women over almost 30 years is nine times that of the general population (95% confidence interval, 4.7-17). This is similar to the 11-fold elevation in relative risk that was determined after about 15 years of follow-up. All invasive carcinomas have developed in the same area in the same breast. There were two women in whom invasive carcinoma developed between 20 and 30 years after initial biopsy. One other woman had an extensive noncomedo DCIS that was identified 25 years after her initial biopsy, but had no evidence of invasive disease.
CONCLUSIONS: The natural history of small, noncomedo DCIS can last over at least 2 decades, with invasive carcinoma developing at the same site in which DCIS was previously discovered in a significant percentage of women (broadly, between 25%-50%). This is quite different from the natural history of comedo DCIS or any type of DCIS treated purposefully by surgery alone.

Entities:  

Mesh:

Year:  1995        PMID: 8630897     DOI: 10.1002/1097-0142(19951001)76:7<1197::aid-cncr2820760715>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  83 in total

Review 1.  The p53 tumor suppressor gene in ductal carcinoma in situ of the breast.

Authors:  J F Simpson; D L Page
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  The biology of incipient, pre-invasive or intraepithelial neoplasia.

Authors:  William E Grizzle; Sudhir Srivastava; Upender Manne
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 3.  Ductal carcinoma in situ of the breast.

Authors:  M J Silverstein
Journal:  BMJ       Date:  1998-09-12

4.  Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis.

Authors:  I Kong; S A Narod; C Taylor; L Paszat; R Saskin; S Nofech-Moses; D Thiruchelvam; W Hanna; J P Pignol; S Sengupta; L Elavathil; P A Jani; S J Done; S Metcalfe; E Rakovitch
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

5.  Risk stratification of ductal carcinoma in situ using whole-lesion histogram analysis of the apparent diffusion coefficient.

Authors:  Jin You Kim; Jin Joo Kim; Ji Won Lee; Nam Kyung Lee; Geewon Lee; Taewoo Kang; Heesung Park; Yo Han Son; Robert Grimm
Journal:  Eur Radiol       Date:  2018-08-02       Impact factor: 5.315

6.  Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ.

Authors:  Jennifer A Ligibel; Ann Partridge; Anita Giobbie-Hurder; Mehra Golshan; Karen Emmons; Eric P Winer
Journal:  Ann Surg Oncol       Date:  2008-10-24       Impact factor: 5.344

7.  Ductal carcinoma in situ of the breast: immune cell composition according to subtype.

Authors:  Marie Colombe Agahozo; Mieke R van Bockstal; Floris H Groenendijk; Thierry P P van den Bosch; Pieter J Westenend; Carolien H M van Deurzen
Journal:  Mod Pathol       Date:  2019-08-02       Impact factor: 7.842

Review 8.  Genetically engineered mouse models of mammary intraepithelial neoplasia.

Authors:  R D Cardiff; D Moghanaki; R A Jensen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

Review 9.  Historical and epidemiologic background of human premalignant breast disease.

Authors:  D L Page; R A Jensen; J F Simpson; W D Dupont
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

10.  Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.

Authors:  Yunn-Yi Chen; Sandy DeVries; Joseph Anderson; Juan Lessing; Rebecca Swain; Koei Chin; Veronica Shim; Laura J Esserman; Frederic M Waldman; E Shelley Hwang
Journal:  BMC Cancer       Date:  2009-08-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.